Ovid Therapeutics Inc. (OVID)
| Market Cap | 431.14M+46.2% |
| Revenue (ttm) | n/a-76.2% |
| Net Income | n/a+9.7% |
| EPS | n/a+10.4% |
| Shares Out | 186.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 258,556 |
| Open | 2.32 |
| Previous Close | 2.36 |
| Day's Range | 2.29 - 2.33 |
| 52-Week Range | 1.18 - 3.11 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 6.67(+188.74%) |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$OVID stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OVID holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OVID's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OVID Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OVID Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| OV329 | $3.41M | 38.38% |
| OV4071 | $2.56M | 28.86% |
| Legal and professional fees | $2.19M | 24.64% |
| KCC2 library | $604.00K | 6.80% |
| Other programs | $117.00K | 1.32% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OVID patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OVID from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OVID
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $15.09M |
| IWMiShares Russell 2000 ETF | $10.12M |
| XBIState Street SPDR S&P Biotech ETF | $6.89M |
| VXFVanguard Extended Market ETF | $5.28M |
| VTWOVanguard Russell 2000 ETF | $2.35M |
| IWCiShares Micro-Cap ETF | $1.23M |
Estimated from each fund’s disclosed top holdings × AUM
OVID Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OVID’s recent data — informational, not investment advice